© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lenalidomide/Rituximab Induction as Effective as Rituximab Plus Chemo in Follicular Lymphoma Subset
August 04, 2020
Lenalidomide in combination with rituximab (Rituxan, R2) induction has the ability to achieve high rates of complete molecular response (CMR), similar to rituximab plus chemotherapy, when used as frontline therapy in patients with follicular lymphoma (FL), according to results from the phase 3 RELEVANCE trial (NCT01650701).
Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point
August 04, 2020
Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.
FDA Grants Fast Track Designation to BST-236 for Older Adults With Acute Myeloid Leukemia
August 04, 2020
The FDA has granted a Fast Track designation to BST-236 for the treatment of patients with acute myeloid leukemia who are 75 years or older or have comorbidities that preclude the use of intensive induction chemotherapy.
Multiple Therapies Show Responses in Lung Cancer With ROS1 Fusions
August 03, 2020
Ben Levy, MD, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib for lung cancer with ROS1 fusions and how to treat them.
Salvage Blinatumomab Therapy Generates Durable Responses in Relapsed/Refractory DLBCL
August 03, 2020
Blinatumomab as salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma may induce durable complete responses and a survival benefit, according to a pooled analysis of 3 clinical trials.
FDA Grants Orphan Drug Designation for SM-88 for Treatment of Pancreatic Cancer
August 03, 2020
The FDA has granted an Orphan Drug designation to SM-88 for the potential treatment of patients with pancreatic cancer.
Pembrolizumab Demonstrated Complete Responses in Non-Muscle Invasive Bladder Cancer
August 03, 2020
The immune checkpoint inhibitor pembrolizumab appeared well-tolerated with encouraging antitumor activity as treatment of patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin, according to the updated follow-up from the phase 2 KEYNOTE-057 clinical trial.
APOLLO Trial Confirms Benefit of Daratumumab Plus Pd in R/R Multiple Myeloma
August 03, 2020
Updated findings from phase 3 APOLLO show an improvement in progression-free survival with daratumumabe plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone alone.
A 67-Year-Old Woman With Differentiated Thyroid Cancer
August 03, 2020
Lori Wirth, MD, provides insight on the case of a 67-year-old woman with differentiated thyroid cancer and examines the management of radioiodine-refractory disease.
Single-Dose Netupitant/Palonosetron Bests 3-Day Aprepitant-Based Regimen to Prevent CINV
August 02, 2020
A single-dose combination of netupitant/palonosetron demonstrated better efficacy compared with a 3-day aprepitant-based regimen, according to results of a pooled analysis of multiple phase 2/3 studies investigating the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
FDA Approves Tafasitamab/Lenalidomide for R/R DLBCL
August 01, 2020
The FDA has approved tafasitamab-cxix in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specific, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant.
Recommendations for Managing Patients With Lung Cancer During COVID-19 Era
July 31, 2020
In response to the COVID-19 pandemic, the European Society of Medical Oncology has published recommendations for the management of patients with lung cancer to maintain high-quality standards of treatment.